NVO news sentiment

#142Tone

finance.yahoo.comDirect company coverage

Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales

DowngradeEarningsPharma

Published

12 Aug 2026 17:29

Catalyst

Analyst action

Evidence role

Direct company coverage

Duplicates

1 consolidated

#240Tone

finance.yahoo.comDirect company coverage

European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading

European equities traded in the US as American depositary receipts were edging lower late Wednesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Published

12 Aug 2026 15:11

Catalyst

Analyst action

Evidence role

Direct company coverage

Duplicates

1 consolidated

#373Tone

finance.yahoo.comDirect company coverage

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity franchise. Notably, sales of injectable Wegovy for obesity were flat year over year in the second quarter, reflecting intensifying competition from rival Eli Lilly's LLY Zepbound injection and raising concerns about Novo Nordisk's ability to sustain momentum in the highly competitive GLP-1 market. Novo

DiabetesEarningsFourth QuarterGuidanceObesityPharma

Published

12 Aug 2026 15:10

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#450Tone

finance.yahoo.comDirect company coverage

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 20

EarningsGuidanceObesityOncologyPharmaRevenue Growth

Published

12 Aug 2026 15:03

Catalyst

Deals and strategy

Evidence role

Direct company coverage

Duplicates

1 consolidated

#561Tone

finance.yahoo.comDirect company coverage

Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck, Novo Nordisk, Okta, and More

Pre-Market Stock Futures: Futures are trading modestly higher as we have arrived at the day everyone on Wall Street has circled on their calendars. The July consumer price index will be released at 8:30 AM EDT, and the producer price index will be released at the same time tomorrow. Economists forecast headline CPI to rise 0.1% month-over-month and 3.4% year-over-year, with core CPI expected to increase 0.2% month-over-month and 2.5% year-over-year. One thing is for sure; if the numbers come in hot and above expectations, the stock market could see a bout of heavy selling. All of the major ind

CryptoEarningsPrice TargetPrice TargetUpgrade Downgrade

Published

12 Aug 2026 11:53

Catalyst

Analyst action

Evidence role

Direct company coverage

Duplicates

1 consolidated

#672Tone

finance.yahoo.comDirect company coverage

Eli Lilly Scores Major Win in Weight-Loss Drug Race

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's opportunity beyond injectable drugs such as Zepbound while giving patients a potentially simpler oral option in one of the pharmaceutical industry's fastest-growing markets. Warning! GuruFocus has detected 6 Warning Signs with INTC. Is LLY fairly valued? Test your thesis with our free DCF calculator.

Fda ApprovalObesityPharmaRegulation

Published

11 Aug 2026 19:07

Catalyst

Regulatory and legal

Evidence role

Direct company coverage

Duplicates

1 consolidated

#767Tone

finance.yahoo.comDirect company coverage

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Published

11 Aug 2026 15:26

Catalyst

Analyst action

Evidence role

Direct company coverage

Duplicates

1 consolidated

#857Tone

finance.yahoo.comDirect company coverage

Lilly Takes Its Weight-Loss Pill Battle Overseas

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's Wegovy tablet in one of Europe's biggest drug marketplaces.Foundayo will initially be provided by private prescription. Availability will be wider via the U.K.'s National Health Service, subject to a review of cost efficiency.Lilly is banking on convenience to help it catch up with Novo. You can take Foundayo

Fda ApprovalHealthcarePharmaUK Approval

Published

11 Aug 2026 15:12

Catalyst

Regulatory and legal

Evidence role

Direct company coverage

Duplicates

1 consolidated

#933Tone

finance.yahoo.comDirect company coverage

Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns for Zepbound and Mounjaro. While both pharmaceutical giants continue to deliver massive top-line growth, a look at their underlying fundamentals shows that one company is clearly pulling ahead in execution, clinical trial

Clinical TrialsFinancial ResultsLawsuitNet IncomeObesity TreatmentPharma

Published

11 Aug 2026 12:44

Catalyst

Regulatory and legal

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1047Tone

finance.yahoo.comDirect company coverage

Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery

Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development teams to streamline the process of bringing new medicines to market. As part of this agreement, AWS becomes Novo Nordisk's preferred cloud provider and strategic AI partner, leveraging AWS's AI technologies to compress timelines from drug target identification to clinica

AICloudEarnings

Published

11 Aug 2026 12:38

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1171Tone

nasdaq.comDirect company coverage

NVO Crosses Above Average Analyst Target

In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.48, changing hands for $47.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 10 different analyst

EtfsMarketsPrice TargetPrice TargetRatingsStocks

Published

11 Aug 2026 11:43

Catalyst

Analyst action

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1261Tone

finance.yahoo.comDirect company coverage

Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?

For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and reduce dependence on overseas supply chains, manufacturing has become more of a competitive advantage than an operational consideration. That shift creates a new question for investors. If domestic manufacturing becomes a larger determinant of pricing, regulatory flexibility, and suppl

FdaManufacturingObesity DrugsPharmaRevenue GrowthShareholder

Published

10 Aug 2026 22:21

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1354Tone

nasdaq.comDirect company coverage

Why Eli Lilly Topped the Market Today

Key Points This market has a population of almost 60 million. While the drug isn't the first of its type to be sold in that country, it will have Lilly's considerable marketing power behind it.10 stocks we like better than Eli Lilly › Eli Lilly(NYSE: LLY) had a fine start to the trading week. On Monday, its stock rose by almost 4% on news that a key European regulator had approved one of its star medications. That also provided plenty of optimism for these types of drugs, which have been hotly popular for years now. The popular pill The product in question is Lilly's Foundayo, its first weight

EuropeMarketsObesity TreatmentsPharmaRegulation

Published

10 Aug 2026 22:13

Catalyst

Regulatory and legal

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1467Tone

finance.yahoo.comDirect company coverage

Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare's fastest-growing markets. Yet another competitive advantage for investors to keep in mind is manufacturing. During the early stages of the GLP-1 boom, demand consistently exceeded supply. Shortages of Wegovy, Ozempic, Mounjaro, and Zepbound demonstrated that developing a breakthro

ManufacturingObesity MarketPharma

Published

10 Aug 2026 21:39

Catalyst

Macro sensitivity

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1526Tone

finance.yahoo.comDirect company coverage

Hims Stock Falls on Earnings. Why a Guidance Hike Isn’t Enough.

Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications. Continue Reading

HealthcareRestructuring

Published

10 Aug 2026 21:12

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1646Tone

finance.yahoo.comDirect company coverage

Eli Lilly Stock Rises 2.1% as UK Clears Obesity Pill

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) just added another weapon to its obesity arsenal. The pharmaceutical giant received British authorization for Foundayo on Monday, making the U.K. the first European country to clear the once-daily orforglipron tablet for weight management and type 2 diabetes. Lilly shares rose approximately 2.1% in regular trading. The appeal is easy to understand: no injection. Foundayo targets GLP-1 while giving patients an oral alternative to Lilly's blockbuster Mounjaro and Zepbound. The pill entered the U.S. market in April and generated $98 m

Fda ApprovalGlp 1ObesityPharmaRevenue Outlook

Published

10 Aug 2026 19:35

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1767Tone

finance.yahoo.comDirect company coverage

European Stocks Close Mixed in Monday Trading as Investors Monitor Middle East War Developments

The European stock markets closed mixed in Monday trading as investors continue to gauge development PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Published

10 Aug 2026 15:38

Catalyst

Analyst action

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1850Tone

finance.yahoo.comDirect company coverage

This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading

Published

10 Aug 2026 14:12

Catalyst

Market update

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1926Tone

finance.yahoo.comDirect company coverage

Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock

Pfizer PFE stock has risen 6.9% since it announced second-quarter 2026 results on Aug. 4. Pfizer delivered a solid second quarter, beating estimates for both earnings and revenues. While earnings growth was flat year over year, revenues rose 1% on an operational basis. Strength in non-COVID products continued to offset declining sales of its COVID products, Comirnaty (COVID-19 vaccine - in partnership with BioNTech [BNTX]) and Paxlovid (oral antiviral). Excluding sales from BioNTech-partnered Comirnaty and Paxlovid, revenues increased 5% operationally. Pfizer also raised the lower end of its 2

EarningsEarnings GrowthEarnings Per ShareObesityOncologyPatent Cliff

Published

10 Aug 2026 13:17

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2029Tone

finance.yahoo.comDirect company coverage

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Inc. -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients – -- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027-- -- In June 2026 Company announced a clinical supply agreement with Novo Nordisk for its Phase 2b PLATEAU clinical trial -- -- In August 2026 Company announced USPTO notice of allowance for key U.S. patent for enobosarm and semaglutide; when issued, U.S. patent protection until at least October 2044 -- -- Company to host conference call and webcast t

BiopharmaceuticalsClinical TrialsFinancial ResultsFourth QuarterObesityOperating Income

Published

10 Aug 2026 10:30

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2167Tone

finance.yahoo.comDirect company coverage

Update: Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date

(Updates with day of announcement in first paragraph, Novo Nordisk's affiliation in the second paragraph, and latest stock moves in the fourth paragraph.)Scholar Rock Holding (SRRK) said Friday that the FDA review of its apitegromab Biologics License Application for spinal Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now

BiotechFda Approval

Published

10 Aug 2026 09:19

Catalyst

Analyst action

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2268Tone

finance.yahoo.comDirect company coverage

Nvidia, Eli Lilly, and Disney Show It’s Time to Back the Top Dogs

Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now. Continue Reading

Published

10 Aug 2026 05:00

Catalyst

Market update

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2335Tone

finance.yahoo.comDirect company coverage

Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Amazon.com Inc.'s Amazon Pharmacy will offer eligible Medicare beneficiaries weight-loss drugs for $50 per month through a new federal program aimed at expanding access. The company announced on Thursday that the service would automate eligibility checks, prior authorizations, and billing, while providing home delivery and in-store pickup to streamline access. Amazon Pharmacy will begin enrollment for eligible patients after they add their insurance and Medicare information and their clinician

Digital HealthcarePharmacyReal EstateWeight Loss

Published

10 Aug 2026 01:31

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2443Tone

seekingalpha.comDirect company coverage

Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus

Wall Street’s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 1.92% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: TOP GAINERS: Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +15.04% Veeva Systems (VEE

Consensus EstimateEarningsEarnings Per ShareGuidanceHealthcareM A

Published

09 Aug 2026 13:05

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2530Tone

seekingalpha.comDirect company coverage

Top global stories this week: BP, SoftBank among notable names

US stock indexes ended the week higher supported by a rally in mega-cap technology stocks, a rebound in Treasury securities and robust corporate earnings. By the end of the week, geopolitical tensions involving Iran pushed crude oil prices toward $78 per barrel, raising fears that higher energy costs could stoke inflation and delay central bank rate cuts. For the week, the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) and Nasdaq (COMP:IND [https://seekingalpha.com/symbol/COMP:IND]) rose 3% and 3.9%, while Dow (DJI [https://seekingalpha.com/symbol/DJI]) booked a 1.8% uptick. Across th

AcquisitionEarningsEarnings NewsGuidanceOn The MoveSemiconductors

Published

09 Aug 2026 13:00

Catalyst

Deals and strategy

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2669Tone

finance.yahoo.comDirect company coverage

Novo Nordisk (CPSE:NOVO B) Wins Dutch Injunction Over Compounded Semaglutide Spray

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk (CPSE:NOVO B) secured a Dutch court injunction against Ceban Ziekenhuisfarmacie over an unapproved compounded semaglutide nasal spray. The ruling blocks production and distribution of the compounded nasal spray in the Netherlands for infringing Novo Nordisk's semaglutide patent. The decision reinforces Novo Nordisk's intellectual property position around Wegovy, Ozempic and Rybelsus and limits non approved competitor versions. Patent enforcement around key obesity and

Balance SheetHealthcarePatent EnforcementPharmaShare Price

Published

08 Aug 2026 23:10

Catalyst

Market update

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2734Tone

finance.yahoo.comDirect company coverage

Novo Nordisk A/S Q2 Earnings Call Highlights

Key Points Interested in Novo Nordisk A/S? Here are five stocks we like better. Novo Nordisk raised its 2026 outlook after a better-than-expected start to the year, reporting Q2 adjusted sales of DKK 78.5 billion and 7% growth at constant exchange rates. However, lower realized prices, manufacturing costs and currency effects reduced the adjusted gross margin to 78.2% from 82.7%. Oral Wegovy drove obesity-treatment momentum. The U.S. pill surpassed 5 million prescriptions and captured about 90% of the oral obesity-drug market, while roughly 80% of users were new to GLP-1 treatments; internatio

CardiovascularDiabetesEarningsObesityPharmaceuticals

Published

08 Aug 2026 22:03

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2882Tone

finance.yahoo.comDirect company coverage

BofA points to the Eli Lilly market that could outsize the U.S.

Eli Lilly (LLY) posted a second-quarter result strong enough to shift the debate around its stock. For months, the debate centered on one worry: a slow start for its new obesity pill. That worry did not disappear in the second quarter, but it stopped driving the conversation. Bank of America came out of the earnings call pointing to a different number. The bank thinks the obesity market outside the United States could eventually surpass U.S. sales of the same drugs. For anyone holding LLY or considering it, that international call is worth a closer look. Why Bank of America raised its Eli Lill

Drug DevelopmentEarningsEarnings EstimateObesityPharmaPrice Target

Published

08 Aug 2026 18:33

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2985Tone

seekingalpha.comDirect company coverage

Trending stocks this week as SpaceX, Palantir earnings and jobs data drive markets

[Wall Street New York stock exchange stock market] alexsl Wall Street ended the week higher, with the Dow Jones Industrial Average (DJI [https://seekingalpha.com/symbol/DJI]) and the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) closing at record highs as investors weighed a deluge of corporate earnings, including results from SpaceX (SPCX [https://seekingalpha.com/symbol/SPCX]) and Palantir Technologies (PLTR [https://seekingalpha.com/symbol/PLTR]), alongside weaker-than-expected U.S. payrolls data. U.S. nonfarm payrolls fell by 23,000 in July, missing economists' expectations for a

AIConsensus EstimateEarningsEarnings Per ShareEarnings ReportFourth Quarter

Published

08 Aug 2026 17:12

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#3075Tone

finance.yahoo.comDirect company coverage

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication in this space. However, the drugmaker has been making headlines with its next-gen anti-obesity medicine, retatrutide. Eli Lilly recently announced that it will request approval from the U.S. Food and Drug Administration for retatrutide in the first quarter of 2027. This new product could help Eli Lilly extend its lead over its biggest competitor in this space, Novo Nordisk (NYSE: NVO). Here's the rundown. Best-in-class efficacy In a phase 3 study, retatrutide posted an average

Clinical TrialsEarningsEarnings Per ShareFda ApprovalFinancial ResultsPharma

Published

07 Aug 2026 22:50

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated